Levi & Korsinsky Alerts Regeneron Pharmaceuticals Investors on Class Action Deadline Set for March 2025
Levi & Korsinsky, LLP has recently notified shareholders of Regeneron Pharmaceuticals, Inc. regarding a significant class action securities lawsuit. Investors who faced losses tied to Regeneron's actions between November 2, 2023, and October 30, 2024, are urged to take action before the crucial lead plaintiff deadline of March 10, 2025.
This lawsuit is designed to recover damages for those adversely affected by what attorneys characterize as fraudulent activities by Regeneron. It is alleged that the company made misleading claims and concealed vital aspects regarding their operations, particularly concerning one of their key products, Eylea.
The complaint puts forward that Regeneron engaged in practices where they paid credit card fees to distributors with the stipulation that these distributors would not increase the prices charged to customers using credit cards for Eylea purchases. By doing so, they allegedly offered a price concession that effectively lowered the selling price of Eylea. This allowed Regeneron to claim increased sales for Eylea while misleading stakeholders about the actual pricing dynamics at play.
Furthermore, the complaint highlights that Regeneron’s decisions resulted in a significant overstatement of the Average Selling Price (ASP) of Eylea, leading to violations under the False Claims Act. As a result, statements made by Regeneron's management regarding the company's performance, future prospects, and business operations were materially misleading.
For individuals who suffered financial losses during the specified period, eligibility to act as a lead plaintiff is available until March 10, 2025. However, becoming a lead plaintiff is not required to participate in any recovery that may result from this legal case.
As part of the process, investors do not need to incur any out-of-pocket costs to pursue compensation, as class members may recuperate losses without financial obligations on their part.
Levi & Korsinsky boasts over two decades of expertise in securing substantial recoveries for aggrieved shareholders and a successful history of managing complex securities litigations. With a team of more than 70 professionals, the firm is well-equipped to represent investors' interests. It has consistently ranked among the top securities litigation firms in the United States, indicating a solid track record and commitment to investor rights.
Investors can connect with Joseph E. Levi, Esq. by emailing [email protected] or calling (212) 363-7500 for more details regarding their rights and the ongoing lawsuit against Regeneron Pharmaceuticals, Inc.
With the deadline approaching, it's crucial for affected investors to act promptly to ensure their interests are represented in this significant class action lawsuit.
Class Action Overview
This lawsuit is designed to recover damages for those adversely affected by what attorneys characterize as fraudulent activities by Regeneron. It is alleged that the company made misleading claims and concealed vital aspects regarding their operations, particularly concerning one of their key products, Eylea.
The complaint puts forward that Regeneron engaged in practices where they paid credit card fees to distributors with the stipulation that these distributors would not increase the prices charged to customers using credit cards for Eylea purchases. By doing so, they allegedly offered a price concession that effectively lowered the selling price of Eylea. This allowed Regeneron to claim increased sales for Eylea while misleading stakeholders about the actual pricing dynamics at play.
Regulatory Violations
Furthermore, the complaint highlights that Regeneron’s decisions resulted in a significant overstatement of the Average Selling Price (ASP) of Eylea, leading to violations under the False Claims Act. As a result, statements made by Regeneron's management regarding the company's performance, future prospects, and business operations were materially misleading.
What Affected Investors Should Do
For individuals who suffered financial losses during the specified period, eligibility to act as a lead plaintiff is available until March 10, 2025. However, becoming a lead plaintiff is not required to participate in any recovery that may result from this legal case.
As part of the process, investors do not need to incur any out-of-pocket costs to pursue compensation, as class members may recuperate losses without financial obligations on their part.
Why Choose Levi & Korsinsky?
Levi & Korsinsky boasts over two decades of expertise in securing substantial recoveries for aggrieved shareholders and a successful history of managing complex securities litigations. With a team of more than 70 professionals, the firm is well-equipped to represent investors' interests. It has consistently ranked among the top securities litigation firms in the United States, indicating a solid track record and commitment to investor rights.
Contact Information
Investors can connect with Joseph E. Levi, Esq. by emailing [email protected] or calling (212) 363-7500 for more details regarding their rights and the ongoing lawsuit against Regeneron Pharmaceuticals, Inc.
With the deadline approaching, it's crucial for affected investors to act promptly to ensure their interests are represented in this significant class action lawsuit.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.